Advertisement

Cancer Medications

Here's a growing list of the approved hormone therapies, immunotherapies and targeted therapies for treating cancer. Click on any of the drugs for more info on dosing, side effects and drug interactions.


Quick Filter

*generic version available

E experimental

DRUG Arranon
GENERIC NAME nelarabine
DRUG INDICATION

Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

DRUG Beleodaq
GENERIC NAME belinostat
DRUG INDICATION

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Farydak
GENERIC NAME panobinostat
DRUG INDICATION

Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

DRUG Inqovi
GENERIC NAME decitabine/cedazuridine
DRUG INDICATION

Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.

DRUG Istodax
GENERIC NAME romidepsin
DRUG INDICATION

Istodax is an HDAC inhibitor approved for previously treated cutaneous and peripheral T-cell lymphoma.

DRUG Xpovio
GENERIC NAME selinexor
DRUG INDICATION

Xpovio is the first approved nuclear export inhibitor. It is indicated for the treatment of people with relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

DRUG Zepzelca
GENERIC NAME lurbinectedin
DRUG INDICATION

Zepzelca is an alkylating drug approved for the treatment of metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy.

DRUG Zolinza
GENERIC NAME vorinostat
DRUG INDICATION

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

 

DRUG Arimidex
GENERIC NAME anastrozole
DRUG INDICATION

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

DRUG Aromasin
GENERIC NAME exemestane
DRUG INDICATION

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

DRUG Casodex
GENERIC NAME bicalutamide
DRUG INDICATION

Casodex is an androgen receptor inhibitor approved for metastatic prostate cancer.

DRUG Erleada
GENERIC NAME apalutamide
DRUG INDICATION

Erleada is an androgen receptor inhibitor approved for nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration resistant).

DRUG Eulexin
GENERIC NAME flutamide
DRUG INDICATION

Eulexin is an anti-androgen drug approved for locally confined metastatic prostate cancer.

DRUG Evista
GENERIC NAME raloxifene
DRUG INDICATION

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

DRUG Fareston
GENERIC NAME toremifene
DRUG INDICATION

Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

DRUG Faslodex
GENERIC NAME fulvestrant
DRUG INDICATION

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

DRUG Femara
GENERIC NAME letrozole
DRUG INDICATION

Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

DRUG Firmagon
GENERIC NAME degarelix
DRUG INDICATION

Firmagon is a GnRH receptor blocker approved for advanced prostate cancer.

DRUG Lupron
GENERIC NAME leuprolide
DRUG INDICATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Nilandron
GENERIC NAME nilutamide
DRUG INDICATION

Nilandron is an anti-androgen drug used to treat men with metastatic prostate cancer after surgical castration, or removal of the testicles.

DRUG Nubeqa
GENERIC NAME darolutamide
DRUG INDICATION

Nubeqa is an androgen receptor inhibitor approved for the treatment of nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant).

DRUG Tamoxifen
GENERIC NAME tamoxifen
DRUG INDICATION

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Trelstar
GENERIC NAME triptorelin
DRUG INDICATION

Trelstar is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

DRUG Vantas
GENERIC NAME histrelin
DRUG INDICATION

Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

DRUG Xtandi
GENERIC NAME enzalutamide
DRUG INDICATION

Xtandi is an androgen receptor inhibitor approved for metastatic or nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant), as well as cancer that remains sensitive to testosterone-blocking therapy.

DRUG Zoladex
GENERIC NAME goserelin
DRUG INDICATION

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zytiga
GENERIC NAME abiraterone
DRUG INDICATION

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

DRUG Bavencio
GENERIC NAME avelumab
DRUG INDICATION

Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer—both as maintenance therapy and for patients who progress on chemotherapy—metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

DRUG Imfinzi
GENERIC NAME durvalumab
DRUG INDICATION

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Kymriah
GENERIC NAME tisagenlecleucel
DRUG INDICATION

Kymriah is a CAR-T therapy approved for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults up to age 25 and for relapsed or refractory diffuse large B-cell lymphoma in adults.

DRUG Libtayo
GENERIC NAME cemiplimab-rwlc
DRUG INDICATION

Libtayo is a checkpoint inhibitor approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Pomalyst
GENERIC NAME pomalidomide
DRUG INDICATION

Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.

DRUG Provenge
GENERIC NAME sipuleucel-T
DRUG INDICATION

Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).

DRUG Revlimid
GENERIC NAME lenalidomide
DRUG INDICATION

Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab),

and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Tecartus
GENERIC NAME brexucabtagene autoleucel
DRUG INDICATION

Tecartus is a CAR-T therapy approved for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma.

DRUG Thalomid
GENERIC NAME thalidomide
DRUG INDICATION

Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

DRUG TICE
GENERIC NAME Bacillus Calmette-Guerin
DRUG INDICATION

TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.

DRUG Yervoy
GENERIC NAME ipilimumab
DRUG INDICATION

Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer.

DRUG Yescarta
GENERIC NAME axicabtagene ciloleucel
DRUG INDICATION

Yescarta is a CAR-T therapy approved for relapsed or refractory large B-cell lymphoma (type of non-Hodgkin lymphoma) in adults, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma.

DRUG Adcetris
GENERIC NAME brentuximab vedotin
DRUG INDICATION

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma, classical Hodgkin lymphoma and peripheral T-cell lymphoma.

 

DRUG Afinitor
GENERIC NAME everolimus
DRUG INDICATION

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Alecensa
GENERIC NAME alectinib
DRUG INDICATION

Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).

DRUG Aliqopa
GENERIC NAME copanlisib
DRUG INDICATION

Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.

DRUG Alunbrig
GENERIC NAME brigatinib
DRUG INDICATION

Alunbrig is an anaplastic lymphoma kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer.

DRUG Arzerra
GENERIC NAME ofatumumab
DRUG INDICATION

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Ayvakit
GENERIC NAME avapritinib
DRUG INDICATION

Ayvakit is a kinase inhibitor approved for the treatment of inoperable or metastatic gastrointestinal stromal tumor (GIST) with specific PDGFRA mutations.

DRUG Balversa
GENERIC NAME erdafitinib
DRUG INDICATION

Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.

DRUG Besponsa
GENERIC NAME inotuzuma ozogamicin
DRUG INDICATION

Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.

DRUG Blenrep
GENERIC NAME belantamab mafodotin
DRUG INDICATION

Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

DRUG Blincyto
GENERIC NAME blinatumomab
DRUG INDICATION

Blincyto is a si-specific T-cell engager approved for adults and children with B cell acute lymphoblastic leukemia.

DRUG Bosulif
GENERIC NAME bosutinib
DRUG INDICATION

Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Braftovi
GENERIC NAME encorafenib
DRUG INDICATION

Braftovi is a kinase inhibitor approved as a component of targeted therapy for metastatic melanoma and metastatic colorectal cancer.

DRUG Brukinsa
GENERIC NAME zanubrutinib
DRUG INDICATION

Brukinsa is a BTK kinase inhibitor approved the previously treated adults with mantle cell lymphoma.

DRUG Cabometyx
GENERIC NAME cabozantinib
DRUG INDICATION

Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

DRUG Calquence
GENERIC NAME acalabrutinib
DRUG INDICATION

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

DRUG Campath
GENERIC NAME alemtuzumab
DRUG INDICATION

Campath is a targeted therapy approved for people with B-cell chronic lymphocytic leukemia who were previously treated with other medications. It is no longer commercially available for leukemia, but has been rebranded as Lemtrada for multiple sclerosis.

DRUG Copiktra
GENERIC NAME duvelisib
DRUG INDICATION

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

DRUG Cotellic
GENERIC NAME cobimetinib
DRUG INDICATION

Cotellic is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Zelboraf (vemurafenib).

DRUG Cyramza
GENERIC NAME ramucirumab
DRUG INDICATION

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG Darzalex, Darzalex Faspro
GENERIC NAME daratumumab
DRUG INDICATION

Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.

DRUG Daurismo
GENERIC NAME glasdegib
DRUG INDICATION

Daurismo is a hedgehog pathway inhibitor approved for treatment of acute myeloid leukemia in newly diagnosed patients who can't use intensive chemotherapy.

DRUG Elzonris
GENERIC NAME tagraxofusp-erzs
DRUG INDICATION

Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.

DRUG Empliciti
GENERIC NAME elotuzumab
DRUG INDICATION

Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Enhertu
GENERIC NAME fam-trastuzumab deruxtecan-nxki
DRUG INDICATION

Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for people with inoperable or metastatic HER2-positive breast cancer who were previously treated with at least two other prior anti-HER2 inhibitors.

DRUG Erbitux
GENERIC NAME cetuximab
DRUG INDICATION

Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.

DRUG Gazyva
GENERIC NAME obinutuzumab
DRUG INDICATION

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

DRUG Gilotrif
GENERIC NAME afatinib
DRUG INDICATION

Gilotrif is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations who are being treated for the first time or who have experienced disease progression on chemotherapy.

DRUG Gleevec
GENERIC NAME imatinib
DRUG INDICATION

Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor.

DRUG Herceptin
GENERIC NAME trastuzumab
DRUG INDICATION

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer and gastric or esophageal carcinoma that overexpresses human epidermal growth factor receptor 2.

DRUG Ibrance
GENERIC NAME palbociclib
DRUG INDICATION

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Iclusig
GENERIC NAME ponatinib
DRUG INDICATION

Iclusig is a kinase inhibitor approved for adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia who can't use other kinase inhibitor medications. It has a specific indication for CML or ALL with a T315I gene mutation.

DRUG Idhifa
GENERIC NAME enasidenib
DRUG INDICATION

Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.

DRUG Imbruvica
GENERIC NAME ibrutinib
DRUG INDICATION

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia.

DRUG Inlyta
GENERIC NAME axitinib
DRUG INDICATION

Inlyta is a kinase inhibitor approved for previously treated advanced kidney cancer (renal cell carcinoma).

DRUG Iressa
GENERIC NAME gefitinib
DRUG INDICATION

Iressa is a tyrosine kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

DRUG Kadcyla
GENERIC NAME ado-trastuzumab emtansine
DRUG INDICATION

Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.

DRUG Kisqali
GENERIC NAME ribociclib
DRUG INDICATION

Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Koselugo
GENERIC NAME selumetinib
DRUG INDICATION

Koselugo is a kinase inhibitor approved for treatment of children with neurofibromatosis type 1 who have inoperable neurofibromas (nerve tumors).

DRUG Kyprolis
GENERIC NAME carfilzomib
DRUG INDICATION

Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

DRUG Lenvima
GENERIC NAME lenvatinib
DRUG INDICATION

Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

DRUG Lorbrena
GENERIC NAME lorlatinib
DRUG INDICATION

Lorbrena is an anaplastic lymphoma kinase inhibitor approved for people with previously treated ALK-positive non-small-cell lung cancer.

DRUG Lumoxiti
GENERIC NAME moxetumomab pasudotox
DRUG INDICATION

Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.

DRUG Lynparza
GENERIC NAME olaparib
DRUG INDICATION

Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.

DRUG Mekinist
GENERIC NAME trametinib
DRUG INDICATION

Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

DRUG Mektovi
GENERIC NAME binimetinib
DRUG INDICATION

Mektovi is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Braftovi (encorafenib).

DRUG Monjuvi
GENERIC NAME tafasitamab
DRUG INDICATION

Monjuvi is a CD19-directed monoclonal antibody approved for the treatment of relapsed or refractory (nonresponsive) diffuse large B-cell lymphoma in combination with Revlimid (lenalidomide).

DRUG Mylotarg
GENERIC NAME gemtuzumab ozogamicin
DRUG INDICATION

Mylotarg is a CD33-directed antibody-drug conjugate approved for adults and children with newly diagnosed or relapsed or refractory acute myeloid leukemia.

DRUG Nerlynx
GENERIC NAME neratinib
DRUG INDICATION

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

DRUG Nexavar
GENERIC NAME sorafenib
DRUG INDICATION

Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

DRUG Ninlaro
GENERIC NAME ixazomib
DRUG INDICATION

Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Padcev
GENERIC NAME enfortumab vedotin-ejfv
DRUG INDICATION

Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.

DRUG Pemazyre
GENERIC NAME pemigatinib
DRUG INDICATION

Pemazyre is a kinase inhibitor approved for treatment of advanced or metastatic cholangiocarcinoma that carries a specific gene mutation.

DRUG Perjeta
GENERIC NAME pertuzumab
DRUG INDICATION

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

DRUG Phesgo
GENERIC NAME Pertuzumab/trastuzumab/hyaluronidase
DRUG INDICATION

Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer.

DRUG Piqray
GENERIC NAME alpelisib
DRUG INDICATION

Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.

DRUG Polivy
GENERIC NAME polatuzumab vedotin-piiq
DRUG INDICATION

Polivy is a CD79b-directed antibody-drug conjugate approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and a rituximab product such as Rituxan.

DRUG Portrazza
GENERIC NAME necitumumab
DRUG INDICATION

Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.

DRUG Qinlock
GENERIC NAME ripretinib
DRUG INDICATION

Qinlock is a kinase inhibitor approved for people with previously treated advanced gastrointestinal stromal tumor (GIST).

DRUG Retevmo
GENERIC NAME selpercatinib
DRUG INDICATION

Retevmo is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer and advanced or metastatic thyroid cancer with RET gene fusions or mutations.

DRUG Rituxan
GENERIC NAME rituxumab
DRUG INDICATION

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Rubraca
GENERIC NAME rucaparib
DRUG INDICATION

Rubraca is a PARP inhibitor approved for maintenance treatment of people with recurrent ovarian, fallopian tube or primary peritoneal cancer that is responding to chemotherapy, for previously treated ovarian cancer in patients with harmful BRCA mutations and for previously treated metastatic castration-resistant prostate cancer in people with harmful BRCA mutations.

DRUG Rydapt
GENERIC NAME midostaurin
DRUG INDICATION

Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.

DRUG Sarclisa
GENERIC NAME isatuximab-irfc
DRUG INDICATION

Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.

DRUG Sprycel
GENERIC NAME dasatinib
DRUG INDICATION

Sprycel is a kinas inhibitor approved for adults and children with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia.

DRUG Stivarga
GENERIC NAME regorafenib
DRUG INDICATION

Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

DRUG Sutent
GENERIC NAME sunitib
DRUG INDICATION

Sutent is a kinase inhibitor approved for treatment of gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer (renal cell carcinoma), and for adjuvant treatment of high-risk kidney cancer after surgery.

DRUG Tabrecta
GENERIC NAME capmatinib
DRUG INDICATION

Tabrecta is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with a specific genetic mutation.

DRUG Tafinlar
GENERIC NAME dabrafenib
DRUG INDICATION

Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer.

DRUG Tagrisso
GENERIC NAME osimertinib
DRUG INDICATION

Tagrisso is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time or who have experienced disease progression on a different EGFR inhibitor.

DRUG Talzenna
GENERIC NAME talazoparib
DRUG INDICATION

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

DRUG Tarceva
GENERIC NAME erlotinib
DRUG INDICATION

Tarceva is an EGFR inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations, and as first-line therapy for locally advanced, inoperable or metastatic pancreatic cancer, in combination with gemcitabine chemotherapy.

DRUG Tasigna
GENERIC NAME nilotinib
DRUG INDICATION

Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Tazverik
GENERIC NAME tazemetostat
DRUG INDICATION

Tazverik is an EZH2 methyltransferase inhibitor approved for the treatment of inoperable epithelioid sarcoma (a type of soft tissue cancer) and for relapsed or refractory follicular lymphoma.

DRUG Tibsovo
GENERIC NAME ivosidenib
DRUG INDICATION

Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.

DRUG Torisel
GENERIC NAME temsirolimus
DRUG INDICATION

Torisel is a kinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma).

DRUG Trodelvy
GENERIC NAME sacituzumab govitecan
DRUG INDICATION

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer.

DRUG Tukysa
GENERIC NAME tucatinib
DRUG INDICATION

Tukysa is a kinase inhibitor approved for use in combination therapy for people with previously treated inoperable or metastatic HER2-positive breast cancer, including cancer that has spread to the brain.

DRUG Turalio
GENERIC NAME pexidartinib
DRUG INDICATION

Turalio is a kinase inhibitor approved for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) that is associated with severe functional limitations and cannot be treated with surgery.

DRUG Tykerb
GENERIC NAME lapatanib
DRUG INDICATION

Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

DRUG Vectibix
GENERIC NAME panitumumab
DRUG INDICATION

Vectibix is an EGFR inhibitor approved for treatment of metastatic colorectal cancer without RAS mutations.

DRUG Velcade
GENERIC NAME bortezomib
DRUG INDICATION

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

DRUG Venclexta
GENERIC NAME venetoclax
DRUG INDICATION

Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.

DRUG Verzenio
GENERIC NAME abemaciclib
DRUG INDICATION

Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

DRUG Vizimpro
GENERIC NAME dacomitinib
DRUG INDICATION

Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

DRUG Votrient
GENERIC NAME pazopanib
DRUG INDICATION

Votrient is a multikinase inhibitor approved for the treatment of advanced kidney cancer (renal cell carcinoma) and previously treated soft tissue sarcoma.

DRUG Xalkori
GENERIC NAME crizotinib
DRUG INDICATION

Xalkori is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) or ROS1 positive.

DRUG Xospata
GENERIC NAME gilteritinib
DRUG INDICATION

Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.

DRUG Zaltrap
GENERIC NAME ziv-aflibercept
DRUG INDICATION

Zaltrap is a VEGF inhibitor approved for treatment of metastatic colorectal cancer that progresses after chemotherapy.

DRUG Zejula
GENERIC NAME niraparib
DRUG INDICATION

Zejula is a PARP inhibitor approved for the treatment of advanced ovarian, fallopian

tube or primary peritoneal cancer in people with harmful BRCA mutations or genomic instability, as well as for maintenance therapy for people with recurrent or advanced cancer that is responding to platinum chemotherapy.

DRUG Zelboraf
GENERIC NAME vemurafenib
DRUG INDICATION

Zelboraf is a kinase inhibitor approved for inoperable or metastatic melanoma with BRAF V600E mutations and Erdheim-Chester Disease with BRAF V600 mutations.

DRUG Zydelig
GENERIC NAME idelalisib
DRUG INDICATION

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

DRUG Zykadia
GENERIC NAME ceritinib
DRUG INDICATION

Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).

Advertisement

Hot topics